You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Policy & Regulation
Gossamer Bio reports topline Phase 3 PROSERA results for seralutinib in PAH
Login
Username:

Password:


Related Headlines

Johnson & Johnson submits sBLA to FDA for first-ever treatment for wAIHA

Epredia signs EU distribution deal with Mindpeak for AI pathology software

AlzeCure's ACD440 granted EU orphan drug status for erythromelalgia

Armata Pharmaceuticals' AP-SA02 receives QIDP designation from US FDA

Astellas Pharma signs global strategic collaboration with Vir Biotechnology

Illumina sets out 18-Month NovaSeq X roadmap to boost sequencing performance and scale

Gossamer Bio reports topline Phase 3 PROSERA results for seralutinib in PAH

Novo Nordisk's CagriSema achieves 23% weight loss but misses primary endpoint in REDEFINE 4 trial

NICE recommends epcoritamab for relapsed or refractory follicular lymphoma

AbbVie's VENCLEXTA (venetoclax) and acalabrutinib combination receives US FDA approval to treat CLL

FDA accepts Genentech application for giredestrant combination in ESR1-mutated advanced breast cancer

FDA approves Genentech oral Venclexta plus AstraZeneca's Calquence combination for first-line CLL

Moleculin exercises warrants for USD8.3m gross proceeds

Eupraxia Pharmaceuticals prices USD55m public offering

Lario Therapeutics awarded USD2.4m in grants for neuronal calcium channel research

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2026